Metropolis Healthcare Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Surendran Chemmenkotil

Chief Executive Officer (CEO)

₹52.3m

Compensación total

Porcentaje del salario del CEO	23.9%
Permanencia del CEO	1.3yrs
Participación del CEO	n/a
Permanencia media de la dirección	1.3yrs
Promedio de permanencia en la Junta Directiva	5.6yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Surendran Chemmenkotil en comparación con los beneficios de Metropolis Healthcare?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	₹1b
Sep 30 2023	n/a	n/a	₹1b
Jun 30 2023	n/a	n/a	₹1b
Mar 31 2023	₹52m	₹13m	₹1b

Compensación vs. Mercado: La compensación total de Surendran($USD627.61K) está por encima de la media de empresas de tamaño similar en el mercado Indian ($USD381.18K).

Compensación vs. Ingresos: Datos insuficientes para comparar la compensación de Surendran con los resultados de la empresa.

CEO

Surendran Chemmenkotil

1.3yrs

Permanencia

₹52,318,552

Compensación

Mr. Surendran Chemmenkotil is Chief Executive Officer of Metropolis Healthcare Limited from January 2, 2023. He is a seasoned leader with rich and diverse experience across consumer facing companies such a...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Sushil Shah	Founder & Executive Chairman	18.7yrs	₹18.00m	18.68% ₹ 17.6b
Surendran Chemmenkotil	Chief Executive Officer	1.3yrs	₹52.32m	sin datos
Rakesh Agarwal	Chief Financial Officer	4.4yrs	₹13.83m	sin datos
Ameera Shah	MD & Executive Director	1.3yrs	₹52.40m	0.35% ₹ 334.8m
Nilesh Shah	Group President and Chief of Science & Innovation	no data	sin datos	sin datos
Kannan Alangadan	Chief Operating Officer – Operations	no data	sin datos	sin datos
Kirti Chadha	Chief Scientific Officer & Group CSR Head	no data	sin datos	sin datos
Kamlesh Kulkarni	Company Secretary & Compliance Officer	less than a year	sin datos	sin datos
Jeyasingh Balakrishnan	Head of Public Relations & Corporate Communications	2.6yrs	sin datos	sin datos
Mohan Menon	Chief Marketing Officer	less than a year	sin datos	sin datos
Ishita Medhekar	Chief People Officer	4.3yrs	sin datos	sin datos
H. Ravikumar	Managing Director of RV Metropolis	no data	sin datos	sin datos

1.3yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de 542650 no se considera experimentado ( 1.3 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Sushil Shah	Founder & Executive Chairman	18.7yrs	₹18.00m	18.68% ₹ 17.6b
Ameera Shah	MD & Executive Director	15.9yrs	₹52.40m	0.35% ₹ 334.8m
Anita Ramachandran	Non-Executive Independent Director	3.9yrs	₹1.15m	sin datos
Sanjay Bhatnagar	Non-Executive Independent Director	5.6yrs	₹765.00k	sin datos
Vivek Gambhir	Non-Executive Independent Director	5.6yrs	₹1.19m	0.00028% ₹ 264.1k
Hemant Sachdev	Non-Executive Non-Independent Director	2.9yrs	sin datos	sin datos

5.6yrs

Permanencia media

58yo

Promedio de edad

Junta con experiencia: La junta directiva de 542650 se considera experimentada (5.6 años de antigüedad promedio).

Metropolis Healthcare Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Founder & Executive Chairman recently sold ₹62m worth of stock

Metropolis Healthcare Limited Announces Management Changes

Metropolis Healthcare Limited Announces the Cessation of Milind Sarwate as an Independent Director, Chairman/Member of Audit Committee, Risk Management Committee and Corporate Social Responsibility Committee, Effective September 06, 2023

Metropolis Healthcare Limited, Annual General Meeting, Aug 17, 2023

Metropolis Healthcare Limited Appoints Neha Shah as Interim Company Secretary

Insufficient new directors

Recent updates

Founder & Executive Chairman recently sold ₹62m worth of stock

Third quarter 2024 earnings: EPS misses analyst expectations

Metropolis Healthcare Limited Announces Management Changes

Metropolis Healthcare Limited to Report Q3, 2024 Results on Feb 02, 2024

Upcoming dividend of ₹4.00 per share at 0.5% yield

Price target increased by 7.4% to ₹1,528

Second quarter 2024 earnings: EPS misses analyst expectations

Metropolis Healthcare Limited to Report Q2, 2024 Results on Nov 04, 2023

Metropolis Healthcare Limited Announces the Cessation of Milind Sarwate as an Independent Director, Chairman/Member of Audit Committee, Risk Management Committee and Corporate Social Responsibility Committee, Effective September 06, 2023

Metropolis Healthcare Limited to Report Q1, 2024 Results on Aug 02, 2023

Full year 2023 earnings: EPS and revenues miss analyst expectations

Metropolis Healthcare Limited, Annual General Meeting, Aug 17, 2023

Metropolis Healthcare Limited Appoints Neha Shah as Interim Company Secretary

Insufficient new directors

Price target decreased by 7.5% to ₹1,397

Full year 2023 earnings: EPS and revenues miss analyst expectations

Metropolis Healthcare Limited to Report Q4, 2023 Results on May 16, 2023

Upcoming dividend of ₹8.00 per share at 0.6% yield

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Metropolis Healthcare Limited Declares Interim Dividend for the Financial Year 2022-23

Metropolis Healthcare Limited to Report Q3, 2023 Results on Feb 10, 2023

Second quarter 2023 earnings: EPS misses analyst expectations

Metropolis Healthcare Limited to Report Q2, 2023 Results on Nov 08, 2022

Metropolis Healthcare Limited Announces Resignation of Vijender Singh as Chief Execution Officer

Metropolis Healthcare Limited Proposes to Confirm the Payment of Interim Dividend for the Financial Year Ended March 31, 2022

Price target decreased to ₹1,746

Metropolis Healthcare Limited to Report Q1, 2023 Results on Aug 10, 2022

Metropolis Healthcare Limited Announces Resignation of Chief Executive Officer, Effective November 30, 2022

Full year 2022 earnings: EPS and revenues miss analyst expectations

Metropolis Healthcare Limited, Annual General Meeting, Aug 17, 2022

Metropolis Healthcare Limited to Report Q4, 2022 Final Results on Jul 18, 2022

GSK Velu Reportedly in Talks with Investors, PEs & Banking Firms to Buy Back Metropolis Healthcare

Metropolis Confirms Promoters Have No Intention to Exit the Business

Adani, Apollo Reportedly Explore Bids for Majority Stake in Metropolis

Price target decreased to ₹2,461

Full year 2022 earnings: EPS and revenues miss analyst expectations

Amazon, Flipkart Reportedly in Talks to Buy Stake in Metropolis Healthcare

Metropolis Healthcare Limited to Report Q4, 2022 Results on May 24, 2022

Investor sentiment improved over the past week

Founder & Executive Chairman recently bought ₹100m worth of stock

Investor sentiment deteriorated over the past week

Upcoming dividend of ₹8.00 per share

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Metropolis Healthcare Limited Declares Payment of an Interim Dividend

Metropolis Healthcare Limited to Report Q3, 2022 Results on Feb 11, 2022

Investor sentiment deteriorated over the past week

Insider recently sold ₹820k worth of stock

Price target increased to ₹2,998

Founder & Executive Chairman recently sold ₹1.3b worth of stock

Second quarter 2022 earnings released: EPS ₹11.39 (vs ₹11.88 in 2Q 2021)

High number of new directors

Key Executive recently sold ₹4.8m worth of stock

Insider recently sold ₹1.7m worth of stock

Price target increased to ₹2,789

Full year 2021 earnings released: EPS ₹35.97 (vs ₹25.36 in FY 2020)

Suburban Diagnostics Reportedly in Sale Talks with Dr. Lal PathLabs, Metropolis, Pharmeasy, Others

Company Secretary & Compliance Officer Poonam Tanwani has left the company

Insider recently sold ₹7.8m worth of stock

Price target increased to ₹2,466

Full year 2021 earnings released: EPS ₹35.97 (vs ₹25.36 in FY 2020)

Chief Executive Officer recently sold ₹5.2m worth of stock

Insider recently sold ₹999k worth of stock

Chief Executive Officer recently sold ₹109m worth of stock

Third quarter 2021 earnings released: EPS ₹11.50 (vs ₹8.38 in 3Q 2020)

Revenue and earnings miss expectations

Metropolis Healthcare Limited Revises Constitution of the Nomination and Remuneration Committee, with Effect from February 10, 2021

Metropolis Healthcare Limited to Report Q3, 2021 Results on Feb 10, 2021

Price target raised to ₹2,193

Metropolis Healthcare Limited (NSEI:METROPOLIS) agreed to acquire Dr. Ganesan's Hitech Diagnostic Centre Private Limited from Ganesan Subramanian, Manimegalai Ganesan and Malini Parasuraman for INR 6.2 billion.